Takeda (NYSE:TAK) said on Thursday that Rhonda Pacheco, who was the group vice president of U.S. cardiometabolic health at Eli Lilly, will join the company as president of its U.S. Business Unit starting September 29.
Pacheco will take over from Julie Kim, who is set to become the president and CEO of Takeda in June 2026, as appointed by the Takeda Board of Directors.
Pacheco brings experience from Eli Lilly, where she led successful product launches, including the GLP-1 portfolio for obesity drugs, a commercial success.
With Pacheco stepping in, the company said Kim will temporarily lead the Global Portfolio Division.